MA47125A - Dérivés de pyrazole en tant qu'inhibiteurs de malt1 - Google Patents

Dérivés de pyrazole en tant qu'inhibiteurs de malt1

Info

Publication number
MA47125A
MA47125A MA047125A MA47125A MA47125A MA 47125 A MA47125 A MA 47125A MA 047125 A MA047125 A MA 047125A MA 47125 A MA47125 A MA 47125A MA 47125 A MA47125 A MA 47125A
Authority
MA
Morocco
Prior art keywords
pyrazole derivatives
malt1 inhibitors
malt1
inhibitors
pyrazole
Prior art date
Application number
MA047125A
Other languages
English (en)
Inventor
Brett Douglas Allison
Joseph Kent Barbay
Didier Jean-Claude Berthelot
Peter J Connolly
Maxwell David Cummings
Gaston Diels
James Patrick Edwards
Kevin D Kreutter
Tianbao Lu
Ulrike Philippar
Fang Shen
Johannes Wilhelmus John Fitzgerald Thuring
Tongfei Wu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47125A publication Critical patent/MA47125A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA047125A 2016-12-21 2017-12-20 Dérivés de pyrazole en tant qu'inhibiteurs de malt1 MA47125A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662437384P 2016-12-21 2016-12-21

Publications (1)

Publication Number Publication Date
MA47125A true MA47125A (fr) 2021-04-28

Family

ID=61628454

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047125A MA47125A (fr) 2016-12-21 2017-12-20 Dérivés de pyrazole en tant qu'inhibiteurs de malt1

Country Status (23)

Country Link
US (2) US10954214B2 (fr)
EP (1) EP3558969B1 (fr)
JP (1) JP7138641B2 (fr)
KR (1) KR102583317B1 (fr)
CN (1) CN110214136A (fr)
AR (1) AR110421A1 (fr)
AU (2) AU2017382185C1 (fr)
BR (1) BR112019012355A2 (fr)
CA (1) CA3048027A1 (fr)
CL (1) CL2019001709A1 (fr)
CO (1) CO2019006622A2 (fr)
EA (1) EA201991503A1 (fr)
ES (1) ES2992411T3 (fr)
IL (1) IL267343B2 (fr)
MA (1) MA47125A (fr)
MX (2) MX392673B (fr)
PE (1) PE20191755A1 (fr)
PH (1) PH12019501212A1 (fr)
TN (1) TN2019000192A1 (fr)
TW (1) TWI795381B (fr)
UA (1) UA127920C2 (fr)
UY (1) UY37537A (fr)
WO (1) WO2018119036A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (fr) 2015-12-22 2017-06-29 Incyte Corporation Composes heterocycliques utilises comme immunomodulateurs
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (fr) 2016-05-26 2021-11-24 Incyte Corporation Composés hétérocycliques comme immunomodulateurs
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
WO2018119286A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119221A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Dérivés pyridine utilisés en tant qu'immunomodulateurs
WO2018119236A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Dérivés de triazolo[1,5-a]pyridine en tant qu'immunomodulateurs
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
KR20200105678A (ko) 2017-12-28 2020-09-08 더 제너럴 하스피탈 코포레이션 Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
CN112752756B (zh) 2018-05-11 2024-06-25 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
AU2019289223B2 (en) * 2018-06-18 2023-09-21 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
EA202190055A1 (ru) * 2018-06-18 2021-04-23 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
TW202045008A (zh) * 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途
EP3927324A1 (fr) 2019-02-22 2021-12-29 Janssen Pharmaceutica NV Formulations pharmaceutiques
BR112021016400A2 (pt) * 2019-02-22 2021-10-13 Janssen Pharmaceutica N.V. Forma cristalina de mono-hidrato de 1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil.)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Pd—1/pd—l1抑制劑之鹽
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド[3,2-d]ピリミジン化合物
WO2021080015A1 (fr) * 2019-10-24 2021-04-29 Ono Pharmaceutical Co., Ltd. Modulateurs de la fonction des canaux trek (canaux k+ associés à twik)
ES3055177T3 (en) * 2019-10-30 2026-02-10 Biogen Ma Inc Condensed pyridazine or pyrimidine as btk inhibitors
EP4058461A1 (fr) 2019-11-11 2022-09-21 Incyte Corporation Formes salines et cristallines d'un inhibiteur de pd-1/pd-l1
CA3162140A1 (fr) 2019-11-22 2021-05-27 Janssen Pharmaceutica Nv Procedes d'evaluation de l'efficacite d'inhibiteurs de malt1 a l'aide d'un dosage de translocation nf-kb
KR20220119037A (ko) 2019-11-22 2022-08-26 얀센 파마슈티카 엔.브이. MALT1 억제제의 효능 평가를 위한 NF-kB 조절 유전자 발현 분석
WO2021138298A1 (fr) * 2019-12-30 2021-07-08 Rheos Medicines, Inc. Modulateurs de malt1 et leurs utilisations
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
JP2023539729A (ja) * 2020-08-21 2023-09-19 ヤンセン ファーマシューティカ エヌ.ベー. Malt1阻害剤の非晶質形態及びその製剤
EP4199911A1 (fr) * 2020-08-21 2023-06-28 JANSSEN Pharmaceutica NV Formulations pharmaceutiques comprenant un inhibiteur de malt1 et un mélange de polyéthylèneglycol et d'un acide gras
WO2022081967A1 (fr) * 2020-10-16 2022-04-21 Rheos Medicines, Inc. Modulateurs de malt1 et leurs utilisations
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
JP2023549835A (ja) * 2020-11-12 2023-11-29 モノプテロス セラピューティクス,インコーポレーテッド がんを治療する材料及び方法
GB202018412D0 (en) * 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
WO2022167962A1 (fr) * 2021-02-04 2022-08-11 Aurigene Discovery Technologies Limited Composés de pyrazolyle substitués utiles en tant qu'inhibiteurs de malt-1
EP4301365A1 (fr) * 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Polythérapie utilisant un inhibiteur de malt1 et un inhibiteur de btk
KR20230154227A (ko) 2021-03-03 2023-11-07 얀센 파마슈티카 엔브이 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법
CN117120427B (zh) * 2021-06-18 2026-07-21 上海拓界生物医药科技有限公司 一种malt1抑制剂及其制备方法和用途
EP4368618A1 (fr) * 2021-07-05 2024-05-15 Betta Pharmaceuticals Co., Ltd Amides d'aryle ou d'hétéroaryle à six chaînons, et composition et utilisation de ceux-ci
CN117715898A (zh) * 2021-07-05 2024-03-15 贝达药业股份有限公司 六元芳基或杂芳基酰胺类化合物及其组合物和用途
WO2023016995A1 (fr) 2021-08-09 2023-02-16 Janssen Pharmaceutica Nv Compositions destinées à être utilisées dans le traitement de malignités des lymphocytes b
CN113912511B (zh) * 2021-11-29 2024-02-13 广东广康生化科技股份有限公司 一种联苯肼酯中间体的合成方法
JP2025501056A (ja) * 2021-12-30 2025-01-17 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 三環系誘導体阻害剤、その製造方法と応用
KR20240144146A (ko) 2022-02-02 2024-10-02 오노 야꾸힝 고교 가부시키가이샤 Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
CN119095837A (zh) * 2022-02-03 2024-12-06 希四克斯探索有限公司 作为malt1抑制剂的杂环衍生物
TW202425968A (zh) * 2022-08-26 2024-07-01 美商熱點醫療公司 吡唑基磺醯胺化合物及其在療法中之用途
TW202430031A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
TW202430514A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
JP2025539452A (ja) 2022-11-30 2025-12-05 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺微生物テトラヒドロイソキノリン誘導体
CN118206543A (zh) * 2022-12-15 2024-06-18 江苏恒瑞医药股份有限公司 一种苯并[c][1,2,5]噁二唑化合物的结晶形式及其制备方法
CN118206538A (zh) * 2022-12-15 2024-06-18 江苏恒瑞医药股份有限公司 一种苯并[c][1,2,5]噁二唑化合物与酒石酸复合物及其晶型
CN120418243A (zh) * 2022-12-16 2025-08-01 江苏恒瑞医药股份有限公司 一种Malt1抑制剂的磷酸酯前药
TW202515550A (zh) * 2023-06-29 2025-04-16 大陸商上海翰森生物醫藥科技有限公司 三并環類抑制劑與抗癌劑在製備抗腫瘤藥物中的聯合應用
TW202515873A (zh) * 2023-06-29 2025-04-16 大陸商上海翰森生物醫藥科技有限公司 一種三并環類衍生物抑制劑的晶型及其製備方法
WO2025069270A1 (fr) * 2023-09-27 2025-04-03 日本新薬株式会社 Composé d'azaindole et médicament
AU2024357109A1 (en) 2023-10-06 2026-03-12 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor
WO2025114167A1 (fr) 2023-11-28 2025-06-05 Syngenta Crop Protection Ag Dérivés de pyrazole microbiocides
WO2025174889A1 (fr) * 2024-02-13 2025-08-21 Board Of Regents, The University Of Texas System Inhibiteurs doubles de malt1 et de btk
WO2025191053A1 (fr) 2024-03-14 2025-09-18 Syngenta Crop Protection Ag Dérivés de pyrazole microbiocides
WO2025210095A1 (fr) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Composés de tétrahydroisoquinoléine microbiocides
WO2025210096A1 (fr) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Compositions fongicides

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
GB9721964D0 (en) * 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
AU2002363250A1 (en) 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
EP1622571A4 (fr) * 2003-04-30 2012-05-02 Agensys Inc Acides nucleiques et proteines correspondantes appelees 109p1d4 utiles dans le traitement et la detection du cancer
EP1617840A4 (fr) 2003-05-01 2008-08-20 Bristol Myers Squibb Co Composes pyrazole-amide utiles en tant qu'inhibiteurs de kinase
EP1847531A4 (fr) 2005-02-09 2009-04-22 Takeda Pharmaceutical Derive de pyrazole
CN100526430C (zh) 2005-10-19 2009-08-12 中国石油化工股份有限公司 一种生产清洁汽油的方法
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
KR20090007347A (ko) 2006-03-22 2009-01-16 버텍스 파마슈티칼스 인코포레이티드 증식성 장애의 치료를 위한 c-MET 단백질 키나제 억제제
US20090253673A1 (en) 2006-07-12 2009-10-08 Min Ge Substituted Pyrazoles as Ghrelin Receptor Antagonists
CN101583601B (zh) 2007-01-17 2013-06-05 香港科技大学 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物
US8153798B2 (en) 2007-03-09 2012-04-10 High Point Pharmaceuticals, Llc Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
CN101366715A (zh) 2007-08-15 2009-02-18 上海医药工业研究院 一种雷帕霉素组合物及其制备方法
EP2222326B2 (fr) 2007-11-21 2015-02-25 Vib Vzw Inhibiteurs d'activité protéolytique de malt1 et leur utilisations
TWI607996B (zh) 2008-09-24 2017-12-11 巴地斯顏料化工廠 控制無脊椎害蟲之吡唑化合物
WO2010039039A1 (fr) 2008-10-03 2010-04-08 Clavis Pharma Asa Formulations orales de dérivés de gemcitabine
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
DE102009003954A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2011036885A1 (fr) 2009-09-25 2011-03-31 武田薬品工業株式会社 Composé hétérocyclique
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
WO2011161612A1 (fr) 2010-06-22 2011-12-29 Basf Se Procédé de préparation de 4-hydroxypyridines
WO2012004217A1 (fr) 2010-07-06 2012-01-12 Novartis Ag Composés éthers cycliques utiles comme inhibiteurs de kinase
TW201236685A (en) 2010-11-11 2012-09-16 Daiichi Sankyo Co Ltd New pyrazole amide derivatives
JP6231085B2 (ja) 2012-05-31 2017-11-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト アミノキナゾリン誘導体及びピリドピリミジン誘導体
WO2014033447A2 (fr) 2012-08-29 2014-03-06 Respivert Limited Inhibiteurs de kinase
EA201590916A1 (ru) 2012-11-09 2016-02-29 Корнэлл Юниверсити Низкомолекулярные ингибиторы malt1
WO2014086478A1 (fr) 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibiteurs de la protéase malt1
MX2015008919A (es) 2013-01-10 2015-10-22 Gruenenthal Gmbh Carboxamidas basadas en pirazolilo i como inhibidores del canal de calcio activado por liberacion de calcio (crac).
JP2015096499A (ja) 2013-10-11 2015-05-21 田辺三菱製薬株式会社 医薬組成物
JP6545197B2 (ja) * 2014-05-28 2019-07-17 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびmalt1阻害剤としてのその使用
WO2015192081A1 (fr) 2014-06-13 2015-12-17 Byrd, John C. Biomarqueur permettant de prédire la réponse d'une llc à un traitement avec un inhibiteur de la btk
WO2016005994A2 (fr) 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Composition pharmaceutique comprenant une dispersion solide de médicaments de classe ii bcs avec gelucires
MX2017001656A (es) 2014-08-08 2017-07-24 Pharmacyclics Llc Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
BR112017004897A2 (pt) 2014-09-10 2017-12-12 Glaxosmithkline Ip Dev Ltd compostos inovadores como inibidores rearranjados durante a transfecção (ret)
WO2016090382A1 (fr) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Composés organiques
US10835524B2 (en) 2015-06-24 2020-11-17 University Of Florida Research Foundation, Incorporated Compositions for the treatment of pancreatic cancer and uses thereof
RS63359B1 (sr) 2015-11-06 2022-07-29 Incyte Corp Heterociklična jedinjenja kao inhibitori pi3k-gama
EP3374361A1 (fr) * 2015-11-13 2018-09-19 Novartis AG Nouveaux dérivés de pyrazolo-pyrimidine
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
WO2017151786A1 (fr) 2016-03-01 2017-09-08 University Of Maryland, Baltimore Inhibiteurs de la voie de signalisation wnt pour le traitement de maladies
WO2018020474A1 (fr) 2016-07-29 2018-02-01 Lupin Limited Composés de thiazolo-pyridine substitués en tant qu'inhibiteurs de malt1
WO2018103060A1 (fr) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibiteurs de tyrosine kinase de bruton et leurs procédés d'utilisation
ES2856248T3 (es) 2016-12-21 2021-09-27 Acerta Pharma Bv Inhibidores de imidazopirazina de la tirosina quinasa de Bruton
JOP20190141A1 (ar) 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
AU2017381433B2 (en) 2016-12-21 2024-11-14 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
JOP20190148A1 (ar) 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
EP3576744A1 (fr) 2017-02-01 2019-12-11 Medivir Aktiebolag Applications thérapeutiques d'inhibiteurs de malt1
EP3592731A4 (fr) 2017-03-08 2020-10-07 Cornell University Inhibiteurs de malt1 et leurs utilisations
WO2018226150A1 (fr) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine utilisés en tant qu'inhibiteurs de malt-1
KR20200105678A (ko) 2017-12-28 2020-09-08 더 제너럴 하스피탈 코포레이션 Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함
EP3756268A1 (fr) 2018-02-23 2020-12-30 Industrieanlagen-Betriebsgesellschaft mbH Dispositif de génération d'un champ magnétique, notamment pour un système de charge inductif, et dispositif primaire d'un système de charge inductif pour la charge dynamique de véhicules
EA202190055A1 (ru) 2018-06-18 2021-04-23 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
AU2019289223B2 (en) 2018-06-18 2023-09-21 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
BR112021016400A2 (pt) 2019-02-22 2021-10-13 Janssen Pharmaceutica N.V. Forma cristalina de mono-hidrato de 1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil.)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida
EP3927324A1 (fr) 2019-02-22 2021-12-29 Janssen Pharmaceutica NV Formulations pharmaceutiques
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
CA3162140A1 (fr) 2019-11-22 2021-05-27 Janssen Pharmaceutica Nv Procedes d'evaluation de l'efficacite d'inhibiteurs de malt1 a l'aide d'un dosage de translocation nf-kb
KR20220119037A (ko) 2019-11-22 2022-08-26 얀센 파마슈티카 엔.브이. MALT1 억제제의 효능 평가를 위한 NF-kB 조절 유전자 발현 분석
WO2021138298A1 (fr) 2019-12-30 2021-07-08 Rheos Medicines, Inc. Modulateurs de malt1 et leurs utilisations
JP2023539729A (ja) 2020-08-21 2023-09-19 ヤンセン ファーマシューティカ エヌ.ベー. Malt1阻害剤の非晶質形態及びその製剤
EP4199911A1 (fr) 2020-08-21 2023-06-28 JANSSEN Pharmaceutica NV Formulations pharmaceutiques comprenant un inhibiteur de malt1 et un mélange de polyéthylèneglycol et d'un acide gras
KR20230154227A (ko) 2021-03-03 2023-11-07 얀센 파마슈티카 엔브이 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법
EP4301365A1 (fr) 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Polythérapie utilisant un inhibiteur de malt1 et un inhibiteur de btk

Also Published As

Publication number Publication date
CA3048027A1 (fr) 2018-06-28
AU2017382185C9 (en) 2022-08-04
PE20191755A1 (es) 2019-12-12
JP2020514267A (ja) 2020-05-21
MX2022005827A (es) 2022-06-08
JP7138641B2 (ja) 2022-09-16
IL267343B2 (en) 2023-06-01
EP3558969B1 (fr) 2024-09-18
IL267343A (en) 2019-08-29
TW201835067A (zh) 2018-10-01
AU2022201352A1 (en) 2022-03-24
US12077521B2 (en) 2024-09-03
US10954214B2 (en) 2021-03-23
AR110421A1 (es) 2019-03-27
BR112019012355A2 (pt) 2019-11-26
KR20190093669A (ko) 2019-08-09
CL2019001709A1 (es) 2019-10-04
PH12019501212A1 (en) 2019-12-16
EA201991503A1 (ru) 2019-11-29
TWI795381B (zh) 2023-03-11
WO2018119036A1 (fr) 2018-06-28
EP3558969A1 (fr) 2019-10-30
AU2017382185B2 (en) 2021-12-02
MX392673B (es) 2025-03-24
AU2017382185C1 (en) 2022-08-11
KR102583317B1 (ko) 2023-09-27
UY37537A (es) 2018-06-29
TN2019000192A1 (en) 2020-10-05
US20220315557A1 (en) 2022-10-06
UA127920C2 (uk) 2024-02-14
MX2019007540A (es) 2019-10-24
US20180170909A1 (en) 2018-06-21
CO2019006622A2 (es) 2019-06-28
AU2017382185A1 (en) 2019-06-13
CN110214136A (zh) 2019-09-06
ES2992411T3 (es) 2024-12-12
EP3558969C0 (fr) 2024-09-18

Similar Documents

Publication Publication Date Title
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
EP3558969C0 (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA49013A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
FR25C1047I1 (fr) Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
EP3733671A4 (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA51431A (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA53352A (fr) Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
MA46856A (fr) Dérivés d'indazole utiles en tant qu'inhibiteurs de la diacylglycéride o-acyltransférase 2
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA51133A (fr) Dérivés de pyrrole utilisés en tant qu'inhibiteurs d'acc
MA41542A (fr) Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase